Gabather AB (publ) (GABA.ST)
SEK 0.4
(-3.61%)
SEK 0.4
(-3.61%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -9.43 Million SEK | -10.44% |
| 2022 | -8.54 Million SEK | 49.73% |
| 2021 | -16.99 Million SEK | -15.29% |
| 2020 | -14.74 Million SEK | -3.18% |
| 2019 | -14.28 Million SEK | 29.66% |
| 2018 | -20.31 Million SEK | -104.41% |
| 2017 | -9.93 Million SEK | -25.89% |
| 2016 | -7.89 Million SEK | -32.35% |
| 2015 | -5.96 Million SEK | -130.63% |
| 2014 | -2.58 Million SEK | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | -3.18 Million SEK | -7.39% |
| 2024 Q2 | -1.71 Million SEK | 45.99% |
| 2023 Q3 | -2.81 Million SEK | -73.58% |
| 2023 Q2 | -1.62 Million SEK | 19.68% |
| 2023 Q1 | -2.02 Million SEK | 17.87% |
| 2023 Q4 | -2.96 Million SEK | -5.07% |
| 2023 FY | -9.43 Million SEK | -10.44% |
| 2022 Q4 | -2.46 Million SEK | -18.48% |
| 2022 Q1 | -1.95 Million SEK | 65.04% |
| 2022 Q2 | -2.05 Million SEK | -5.38% |
| 2022 Q3 | -2.07 Million SEK | -1.12% |
| 2022 FY | -8.54 Million SEK | 49.73% |
| 2021 Q4 | -5.57 Million SEK | -47.57% |
| 2021 FY | -16.99 Million SEK | -15.29% |
| 2021 Q1 | -3.45 Million SEK | -3.41% |
| 2021 Q2 | -4.18 Million SEK | -21.01% |
| 2021 Q3 | -3.78 Million SEK | 9.61% |
| 2020 Q4 | -3.34 Million SEK | 24.64% |
| 2020 FY | -14.74 Million SEK | -3.18% |
| 2020 Q3 | -4.43 Million SEK | -67.55% |
| 2020 Q1 | -4.32 Million SEK | -18.01% |
| 2020 Q2 | -2.64 Million SEK | 38.73% |
| 2019 Q2 | -4.16 Million SEK | -11.93% |
| 2019 Q4 | -3.66 Million SEK | -33.84% |
| 2019 Q3 | -2.73 Million SEK | 34.33% |
| 2019 FY | -14.28 Million SEK | 29.66% |
| 2019 Q1 | -3.72 Million SEK | 9.45% |
| 2018 Q3 | -5.16 Million SEK | 15.66% |
| 2018 Q4 | -4.1 Million SEK | 20.41% |
| 2018 FY | -20.31 Million SEK | -104.41% |
| 2018 Q1 | -4.71 Million SEK | -45.15% |
| 2018 Q2 | -6.12 Million SEK | -29.87% |
| 2017 Q4 | -3.24 Million SEK | -82.77% |
| 2017 Q2 | -2.58 Million SEK | -10.63% |
| 2017 Q1 | -2.33 Million SEK | -4.24% |
| 2017 FY | -9.93 Million SEK | -25.89% |
| 2017 Q3 | -1.77 Million SEK | 31.15% |
| 2016 Q1 | -1.62 Million SEK | -16.12% |
| 2016 FY | -7.89 Million SEK | -32.35% |
| 2016 Q2 | -2.23 Million SEK | -37.45% |
| 2016 Q4 | -2.23 Million SEK | -25.18% |
| 2016 Q3 | -1.78 Million SEK | 20.14% |
| 2015 Q2 | -2.06 Million SEK | -68.85% |
| 2015 Q3 | -1.28 Million SEK | 37.77% |
| 2015 Q4 | -1.4 Million SEK | -9.42% |
| 2015 FY | -5.96 Million SEK | -130.63% |
| 2015 Q1 | -1.22 Million SEK | -30.76% |
| 2014 Q2 | -9000.00 SEK | 0.0% |
| 2014 Q4 | -933 Thousand SEK | -19.16% |
| 2014 FY | -2.58 Million SEK | 0.0% |
| 2014 Q3 | -783 Thousand SEK | -8600.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| AcuCort AB | -13.69 Million SEK | 31.072% |
| AlzeCure Pharma AB (publ) | -37.16 Million SEK | 74.609% |
| BioGaia AB (publ) | 365.35 Million SEK | 102.583% |
| Enzymatica AB (publ) | -49.72 Million SEK | 81.023% |
| Enorama Pharma AB (publ) | -44.61 Million SEK | 78.847% |
| Klaria Pharma Holding AB (publ.) | -35.78 Million SEK | 73.628% |
| Moberg Pharma AB (publ) | -21.09 Million SEK | 55.26% |
| Nanexa AB (publ) | -76.39 Million SEK | 87.648% |
| Newbury Pharmaceuticals AB (publ) | -15.4 Million SEK | 38.741% |
| ODI Pharma AB | 355.97 Thousand SEK | 2751.059% |
| Orexo AB (publ) | -128.3 Million SEK | 92.645% |
| Probi AB (publ) | 16.81 Million SEK | 156.109% |
| Swedencare AB (publ) | 58.6 Million SEK | 116.104% |
| Swedish Orphan Biovitrum AB (publ) | 2.4 Billion SEK | 100.392% |
| Toleranzia AB | -7.45 Million SEK | -26.518% |
| Vivesto AB | -367.03 Million SEK | 97.429% |